Know Cancer

or
forgot password

A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects


Phase 2
3 Years
11 Years
Not Enrolling
Both
Warts

Thank you

Trial Information

A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects


Inclusion Criteria:



- Diagnosis of common wart(s)

- Ages between 3 to 11

Exclusion Criteria:

- Other types of wart(s), ie. plantar

- Currently participating in another clinical study

- Chronic viral hepatitis B or C

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment

Outcome Measure:

Clearance of treated common wart(s)

Authority:

United States: Food and Drug Administration

Study ID:

1534-RESI

NCT ID:

NCT00116662

Start Date:

March 2005

Completion Date:

Related Keywords:

  • Warts
  • Wart(s)
  • Common Wart(s)
  • Children
  • Pediatric
  • 3M Pharmaceuticals
  • Resiquimod
  • Warts

Name

Location

ArkansasFayetteville, Arkansas  72703
GeorgiaNewnan, Georgia  30263
IllinoisBuffalo Grove, Illinois  60089
IndianaLafayette, Indiana  47904
KansasWichita, Kansas  67207
MassachusettsBoston, Massachusetts  02114
MissouriSt. Louis, Missouri  63110
UtahLayton, Utah  84041
VermontBurlington, Vermont  05401